Carried out in agreement to a post-marketing requirement by the US Food and Drug Administration (FDA), the trial showed comparable sexual function in these adults treated daily with
As part of the supplemental deal, Triphase will receive additional development funds through a cost sharing arrangement with Celgene. The deal will see Triphase control product development and
Following approval, this product will serve as replacement therapy for patients who suffer from a congenital lack of the normal plasminogen protein and/or its functional activity. The FDA
OliPass is focused on developing antisense medicines based on peptide nucleic acid (PNA) technology. As part of the deal, BMS will make an up-front payment as well as
The company said that ARA 290 activates the natural repair system of the body by activating the Innate Repair Receptor and thereby turning off systemic inflammation and turning
The trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses MBC-11, a lead compound from a technology platform based on bisphosphonate
Under the deal, Aspen will be responsible for securing regulatory and pricing approval, as well as the marketing and distribution of the drug. Iroko Pharmaceuticals president and CEO
FS102 is being developed to treat breast and gastric cancer in HER2-positive patients who do not respond or become resistant to the existing therapies. HER2, a highly validated
The IND was based on a pivotal Phase III protocol for Neutrolin in hemodialysis patients with a central venous catheter. The multi-center, randomized, controlled Phase III clinical trial
Funded by the EU Innovative Medicines Initiative (IMI), the consortium aims to define a standard for the responsible use of dwindling reserves of effective antibiotics. The new consortium
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.